SPONSORED – Neuropathy is becoming a bigger problem for more people than ever before. If you`re suffering from stabbing pain, ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

The new findings show that ADCs ... contributing to chemotherapy-induced peripheral neuropathy. ADCs, a form of guided ...

and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. - Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug ...

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study.

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...